RICHMOND, Calif., Sept. 2, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (SGMO), a leader in therapeutic genome editing, announced today that the company and its collaborator, Shire plc (LSE: SHP, ...
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that data from its program to develop a ZFP Therapeutic(TM) for HIV/AIDS were presented at the 45th Annual Interscience Conference on ...
Partners aim to develop zinc finger protein transcription factor that alters expression of the mutated huntingtin gene. Sangamo BioSciences and the CHDI Foundation are teaming up to develop a ...
Office automation and professional services company, ZFP IT, is helping organisations throughout the Kingdom of Saudi Arabia cut costs and boost their competitive advantage through the use of ...
Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting CHICAGO, June 22 -- Sangamo BioSciences announced today the presentation of ...
RICHMOND, Calif., Jan. 10, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the company completed enrollment of its Phase 2b double-blind, placebo-controlled clinical ...
One key to developing a treatment for Huntington’s disease (HD), according to many researchers, involves the challenging task of reducing the expression of the patient’s mutated copy of the huntingtin ...
Sangamo BioSciences, Inc. has announced the presentation of preclinical data from its ZFP Therapeutic™ program in nerve regeneration at the Fourteenth Annual Conference of the American Society for ...
C 2 H 2 zinc fingers are the most common DNA-binding motif found in the human genome. The Zif268–DNA crystal structure shows how zinc fingers interact with DNA. The fingers act as modular units (each ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results